Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AssigneeAstute Medical, Inc.
InventorsJoseph Anderberg, Paul McPherson, Jeff Gray, Kevin Nakamura, James Patrick Kampf, Thomas Kwan
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulinlike growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.
Claims16
A method comprising:
- (a) obtaining a body fluid sample from a subject having a persistent RIFLE I acute kidney injury or a persistent RIFLE F acute kidney injury;
- and
- (b) detecting a level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the sample,
- wherein the persistent RIFLE I acute kidney injury is an acute kidney injury for a period of 48 hours or more at a minimum RIFLE stage of RIFLE stage I, and
- wherein the persistent RIFLE F acute kidney injury is an acute kidney injury for a period of 48 hours or more at a minimum RIFLE stage of RIFLE stage F.
A method of treating acute kidney injury comprising:
- (a) obtaining a urine sample from a subject;
- (b) detecting a level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the urine sample;
- (c) determining that the subject is at increased risk of future persistence of a RIFLE I acute kidney injury or future persistence of a RIFLE F acute kidney injury based on the level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the urine sample, and
- (d) administering renal replacement therapy to the subject at the increased risk of future persistence of the RIFLE I acute kidney injury or future persistence of the RIFLE F acute kidney injury.
Dependencies are inferred from the claim text.